Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Phase 1a/b Study of BG-C477 in Advanced Solid Tumors
jRCT2031250860Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of BG-C477 in Nonhematologic neoplasms (3 arms), sponsored by BeOne Medicines. Primary endpoints: Phase 1a Safety and Tolerability (AEs and SAEs), Phase 1a Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and 3 more. Started Apr 2026; status: recruiting.
02
Drugs
BG-C477
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031250860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250860.